Reply to Y.-N. Feng et al

Hielke M de Vries¹, Oscar R Brouwer¹, Eva Schaake¹+1

• ¹Hielke M. de Vries, MD, Department of Medical Oncology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands, Department of Urology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Oscar R. Brouwer, MD, PhD, Department of Urology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Eva Schaake, MD, PhD, Department of Radiation Therapy, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; and Michiel S. van der Heijden, MD, PhD, Department of Medical Oncology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands, Department of Molecular Carcinogenesis, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.